论文信息 - TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study - 字舞流文

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

V. Mazzaferro | L. Antonuzzo | M. Aglietta | R. Berardi | A. Zaniboni | G. Cardellino | M. Di Maio | A. Strippoli | L. Fornaro | R. Murialdo | F. Iachetta | S. Lonardi | F. Pietrantonio | S. Tamberi | G. Aprile | A. Spallanzani | C. Cremolini | N. Silvestris | M. Prisciandaro | F. De Vita | G. Frassineti | V. Smiroldo | M. Ratti | A. Raimondi | E. Ongaro | M. Di Bartolomeo | C. Granetto | C. Sposito | F. Pucci | E. Tamburini | Federica Palermo | G. De Manzoni